These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 1984374)

  • 1. A blinded comparison of noninvasive, in vivo phosphorus nuclear magnetic resonance spectroscopy and the in vitro halothane/caffeine contracture test in the evaluation of malignant hyperthermia susceptibility.
    Olgin J; Rosenberg H; Allen G; Seestedt R; Chance B
    Anesth Analg; 1991 Jan; 72(1):36-47. PubMed ID: 1984374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved noninvasive diagnostic testing for malignant hyperthermia susceptibility from a combination of metabolites determined in vivo with 31P-magnetic resonance spectroscopy.
    Payen JF; Bosson JL; Bourdon L; Jacquot C; Le Bas JF; Stieglitz P; Benabid AL
    Anesthesiology; 1993 May; 78(5):848-55. PubMed ID: 8489056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-invasive evaluation of malignant hyperthermia susceptibility with phosphorus nuclear magnetic resonance spectroscopy.
    Olgin J; Argov Z; Rosenberg H; Tuchler M; Chance B
    Anesthesiology; 1988 Apr; 68(4):507-13. PubMed ID: 3354887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility.
    Wappler F; Anetseder M; Baur CP; Censier K; Doetsch S; Felleiter P; Fiege M; Fricker R; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Hopkins PM; Klingler W; Lehmann-Horn F; Nivoche Y; Tegazzin V; Tzanova I; Urwyler A; Weisshorn R; Schulte am Esch J
    Eur J Anaesthesiol; 2003 Jul; 20(7):528-36. PubMed ID: 12884985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
    Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
    Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
    Hartung E; Koob M; Anetseder M; Schoemig P; Krauspe R; Hogrefe G; Engelhardt W
    Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of in vitro contracture testing with ryanodine, halothane and caffeine in malignant hyperthermia and other neuromuscular disorders.
    Hopkins PM; Ellis FR; Halsall PJ
    Br J Anaesth; 1993 Apr; 70(4):397-401. PubMed ID: 8499197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
    Ording H; Bendixen D
    Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia.
    Sato N; Brum JM; Mitsumoto H; DeBoer GE
    Can J Anaesth; 1995 Feb; 42(2):158-62. PubMed ID: 7720160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors of the contracture test for diagnosing malignant hyperthermia in a Brazilian population sample: a retrospective observational study.
    de Mello JM; Andrade PV; Santos JM; Oliveira ASB; Vainzof M; do Amaral JLG; Almeida da Silva HC
    Braz J Anesthesiol; 2023; 73(2):145-152. PubMed ID: 35835312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS.
    Allen GC; Larach MG; Kunselman AR
    Anesthesiology; 1998 Mar; 88(3):579-88. PubMed ID: 9523799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.
    Ording H; Brancadoro V; Cozzolino S; Ellis FR; Glauber V; Gonano EF; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Kozak-Ribbens G; Kress H; Krivosic-Horber R; Lehmann-Horn F; Mortier W; Nivoche Y; Ranklev-Twetman E; Sigurdsson S; Snoeck M; Stieglitz P; Tegazzin V; Urwyler A; Wappler F
    Acta Anaesthesiol Scand; 1997 Sep; 41(8):955-66. PubMed ID: 9311391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic effects on the variability of the halothane and caffeine muscle contracture tests.
    Urwyler A; Censier K; Kaufmann MA; Drewe J
    Anesthesiology; 1994 Jun; 80(6):1287-95. PubMed ID: 8010475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar susceptibility to halothane, caffeine and ryanodine in vitro reflects pharmacogenetic variability of malignant hyperthermia.
    Ginz HF; Girard T; Censier K; Urwyler A
    Eur J Anaesthesiol; 2004 Feb; 21(2):151-7. PubMed ID: 14977348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caffeine and halothane contracture testing in swine using the recommendations of the North American Malignant Hyperthermia Group.
    Allen GC; Fletcher JE; Huggins FJ; Conti PA; Rosenberg H
    Anesthesiology; 1990 Jan; 72(1):71-6. PubMed ID: 2297135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of malignant hyperthermia susceptibility in low-risk subjects. An epidemiologic investigation of caffeine halothane contracture responses. The North American Malignant Hyperthermia Registry.
    Larach MG; Landis JR; Bunn JS; Diaz M
    Anesthesiology; 1992 Jan; 76(1):16-27. PubMed ID: 1729931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ryanodine contracture test may help diagnose susceptibility to malignant hyperthermia.
    Reuter DA; Anetseder M; Müller R; Roewer N; Hartung EJ
    Can J Anaesth; 2003; 50(7):643-8. PubMed ID: 12944436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between the neuroleptic malignant syndrome and malignant hyperthermia.
    Adnet PJ; Krivosic-Horber RM; Adamantidis MM; Haudecoeur G; Adnet-Bonte CA; Saulnier F; Dupuis BA
    Acta Anaesthesiol Scand; 1989 Nov; 33(8):676-80. PubMed ID: 2588999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Halothane-caffeine contracture testing in neuromuscular diseases.
    Heiman-Patterson TD; Rosenberg H; Fletcher JE; Tahmoush AJ
    Muscle Nerve; 1988 May; 11(5):453-7. PubMed ID: 3374516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Detection of peranesthetic malignant hyperthermia by muscle contracture tests and NMR spectroscopy].
    Kozak-Reiss G; Gascard JP; Redouane-Bénichou K
    Ann Fr Anesth Reanim; 1986; 5(6):584-9. PubMed ID: 3826791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.